Exelixis, a biotech firm specializing in oncology, is dedicated to discovering, developing and marketing new cancer treatments in the U.S. The company offers CABOMETYX tablets for patients with advanced renal cell carcinoma who have already received treatment with anti-angiogenic therapy. Additionally, COMETRIQ capsules treat progressive and metastatic medullary thyroid cancer. The medicines the company creates are derived from cabozantinib, which inhibits multiple tyrosine kinases such as MET, AXL, RET and VEGF receptors. Exelixis also offers COTELLIC, an inhibitor of MEK, as a combination regimen to treat advanced melanoma, as well as MINNEBRO, an oral non-steroidal blocker for the mineralocorticoid receptor to treat hypertension in Japan. Exelixis is also in the process of developing additional treatments, including zanzalintinib, an oral tyrosine kinase inhibitor targeting VEGF receptors, MET, AXL, MER, and other kinases that can spur the growth of cancer. They also have XB002, an antibody-drug conjugate composed of a human monoclonal antibody against tissue factor (TF) for treating advanced solid tumors, XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors, and XB002 for the treatment of non-hodgkin's lymphoma. The company has established research collaborations and license agreements with numerous partners such as Takeda Pharmaceutical and Daiichi Sankyo Company. Moreover, they have a clinical development agreement with Sairopa B.V. for ADU-1805. Headquartered in Alameda, California, Exelixis was incorporated in 1994 and was previously known as Exelixis Pharmaceuticals, changing its name in February 2000.
Exelixis's ticker is EXEL
The company's shares trade on the NASDAQ stock exchange
They are based in Alameda, California
There are 51-200 employees working at Exelixis
It is exelixis.com
Exelixis is in the Healthcare sector
Exelixis is in the Biotechnology industry
The following five companies are Exelixis's industry peers: